SK14122000A3 - Substituované benzamidy, ich príprava a použitie - Google Patents

Substituované benzamidy, ich príprava a použitie Download PDF

Info

Publication number: SK14122000A3
Authority: SK; Slovakia
Prior art keywords: phenyl; alkyl; benzamide; branched; unbranched
Prior art date: 1998-04-20

Application number

SK1412-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Wilfried Lubisch

Achim Mller

Hans-J�Rg Treiber

Monika Knopp

Original Assignee

Basf Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-20

Filing date

1999-04-19

Publication date

2001-05-10

1999-04-19 Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft

2001-05-10 Publication of SK14122000A3 publication Critical patent/SK14122000A3/sk

Links

150000003936 benzamides Chemical class 0.000 title claims abstract description 19
229940054066 benzamide antipsychotics Drugs 0.000 title claims abstract description 14
238000004519 manufacturing process Methods 0.000 title claims description 10
239000002852 cysteine proteinase inhibitor Substances 0.000 title claims 2
239000003112 inhibitor Substances 0.000 claims abstract description 31
102000005927 Cysteine Proteases Human genes 0.000 claims abstract description 12
108010005843 Cysteine Proteases Proteins 0.000 claims abstract description 12
150000003839 salts Chemical class 0.000 claims abstract description 5
-1 CF 3 Inorganic materials 0.000 claims description 126
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 82
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
150000001875 compounds Chemical class 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 29
239000001257 hydrogen Substances 0.000 claims description 29
108010032088 Calpain Proteins 0.000 claims description 27
102000007590 Calpain Human genes 0.000 claims description 27
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 21
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 14
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
150000002431 hydrogen Chemical class 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
208000006011 Stroke Diseases 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
208000028867 ischemia Diseases 0.000 claims description 7
125000001624 naphthyl group Chemical group 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
229910052740 iodine Inorganic materials 0.000 claims description 6
208000015122 neurodegenerative disease Diseases 0.000 claims description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
102000005600 Cathepsins Human genes 0.000 claims description 5
108010084457 Cathepsins Proteins 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
230000003683 cardiac damage Effects 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 2
208000003890 Coronary Vasospasm Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
102000000589 Interleukin-1 Human genes 0.000 claims description 2
108010002352 Interleukin-1 Proteins 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
206010063897 Renal ischaemia Diseases 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
206010053648 Vascular occlusion Diseases 0.000 claims description 2
238000002399 angioplasty Methods 0.000 claims description 2
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
125000001246 bromo group Chemical group Br* 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
230000004663 cell proliferation Effects 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000001041 indolyl group Chemical group 0.000 claims description 2
208000001286 intracranial vasospasm Diseases 0.000 claims description 2
238000007912 intraperitoneal administration Methods 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
125000005495 pyridazyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
230000010410 reperfusion Effects 0.000 claims description 2
208000037803 restenosis Diseases 0.000 claims description 2
210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
208000021331 vascular occlusion disease Diseases 0.000 claims description 2
230000003961 neuronal insult Effects 0.000 claims 2
206010019196 Head injury Diseases 0.000 claims 1
208000032843 Hemorrhage Diseases 0.000 claims 1
206010062237 Renal impairment Diseases 0.000 claims 1
208000026278 immune system disease Diseases 0.000 claims 1
208000031225 myocardial ischemia Diseases 0.000 claims 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 43
239000000543 intermediate Substances 0.000 description 28
239000000047 product Substances 0.000 description 28
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
239000000203 mixture Substances 0.000 description 22
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
238000000034 method Methods 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
108010079785 calpain inhibitors Proteins 0.000 description 14
239000011541 reaction mixture Substances 0.000 description 14
239000000243 solution Substances 0.000 description 13
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
239000002253 acid Substances 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
238000003776 cleavage reaction Methods 0.000 description 10
230000007017 scission Effects 0.000 description 10
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
239000011575 calcium Substances 0.000 description 9
229910052791 calcium Inorganic materials 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
238000005160 1H NMR spectroscopy Methods 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
150000001408 amides Chemical group 0.000 description 8
150000002576 ketones Chemical class 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
239000000872 buffer Substances 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
108090000712 Cathepsin B Proteins 0.000 description 6
102000004225 Cathepsin B Human genes 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
150000001298 alcohols Chemical class 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000000126 substance Substances 0.000 description 6
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
150000001299 aldehydes Chemical class 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000030833 cell death Effects 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
239000003257 excitatory amino acid Substances 0.000 description 5
230000002461 excitatory amino acid Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
238000012360 testing method Methods 0.000 description 5
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
239000002555 ionophore Substances 0.000 description 4
230000000236 ionophoric effect Effects 0.000 description 4
125000000468 ketone group Chemical group 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
229940124530 sulfonamide Drugs 0.000 description 4
150000003456 sulfonamides Chemical class 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000006859 Swern oxidation reaction Methods 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
150000001414 amino alcohols Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000003978 infusion fluid Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
108010068164 mu-calpain Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
238000001262 western blot Methods 0.000 description 3
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
229940121926 Calpain inhibitor Drugs 0.000 description 2
102100035037 Calpastatin Human genes 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
239000012722 SDS sample buffer Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001336 alkenes Chemical class 0.000 description 2
150000001345 alkine derivatives Chemical class 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
238000009835 boiling Methods 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 2
108010044208 calpastatin Proteins 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
150000001733 carboxylic acid esters Chemical class 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000003618 cortical neuron Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
201000006938 muscular dystrophy Diseases 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
230000035778 pathophysiological process Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000010118 platelet activation Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000000844 transformation Methods 0.000 description 2
COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
OQQBVNUWYANEQS-AATRIKPKSA-N 2-[(e)-2-pyridin-4-ylethenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1\C=C\C1=CC=NC=C1 OQQBVNUWYANEQS-AATRIKPKSA-N 0.000 description 1
FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
CJCOBMTYEDBBSY-UHFFFAOYSA-N 2-phenoxybenzamide Chemical compound NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 CJCOBMTYEDBBSY-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
KKLUFCAOPPZISL-UHFFFAOYSA-N 3-(naphthalen-2-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=C1 KKLUFCAOPPZISL-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
102000003678 AMPA Receptors Human genes 0.000 description 1
108090000078 AMPA Receptors Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
BXIPERJNANHOLX-UHFFFAOYSA-N C1=CC(C(=O)NC(CCCC)C(=O)CNC(C)=O)=CC=C1NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical compound C1=CC(C(=O)NC(CCCC)C(=O)CNC(C)=O)=CC=C1NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 BXIPERJNANHOLX-UHFFFAOYSA-N 0.000 description 1
NCAMRWIPRFLRJS-UHFFFAOYSA-N C1=CC(C(=O)NC(CCCC)C(=O)CNC(C)=O)=CC=C1OCC1=CC=C(C=CC=C2)C2=C1 Chemical compound C1=CC(C(=O)NC(CCCC)C(=O)CNC(C)=O)=CC=C1OCC1=CC=C(C=CC=C2)C2=C1 NCAMRWIPRFLRJS-UHFFFAOYSA-N 0.000 description 1
WEUGJICEEMNWNN-UHFFFAOYSA-N C=1C=C(OCC=2C=C3C=CC=CC3=CC=2)C=CC=1C(=O)NC(CCCC)C(=O)CNC(=O)C1=CC=CC=C1 Chemical compound C=1C=C(OCC=2C=C3C=CC=CC3=CC=2)C=CC=1C(=O)NC(CCCC)C(=O)CNC(=O)C1=CC=CC=C1 WEUGJICEEMNWNN-UHFFFAOYSA-N 0.000 description 1
STQXWHIZGDIOMN-UHFFFAOYSA-N C=1C=CC=CC=1C(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1C(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1C1=CC=CC=C1 STQXWHIZGDIOMN-UHFFFAOYSA-N 0.000 description 1
XEKIMBJXVVZMKR-UHFFFAOYSA-N C=1C=CC=CC=1C(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 Chemical compound C=1C=CC=CC=1C(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 XEKIMBJXVVZMKR-UHFFFAOYSA-N 0.000 description 1
PEKPNRQDWHLNQG-UHFFFAOYSA-N CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=C1 Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=C1 PEKPNRQDWHLNQG-UHFFFAOYSA-N 0.000 description 1
DBEHZDFEIKIRFZ-UHFFFAOYSA-N CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC(NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=C1 Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC(NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=C1 DBEHZDFEIKIRFZ-UHFFFAOYSA-N 0.000 description 1
ZOOYCMADWPUASC-UHFFFAOYSA-N CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1C1=CC=CC=C1 Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1C1=CC=CC=C1 ZOOYCMADWPUASC-UHFFFAOYSA-N 0.000 description 1
USOYLGUDXAHCNZ-UHFFFAOYSA-N CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 USOYLGUDXAHCNZ-UHFFFAOYSA-N 0.000 description 1
AGVJGJRQRKVCLG-WCWDXBQESA-N CCN(CC)CC1=CC=C(C=C1)/C=C/C2=CC=CC=C2C(=O)NC(CC3CCCCC3)C(=O)CNS(=O)(=O)C4=CC=CC=C4 Chemical compound CCN(CC)CC1=CC=C(C=C1)/C=C/C2=CC=CC=C2C(=O)NC(CC3CCCCC3)C(=O)CNS(=O)(=O)C4=CC=CC=C4 AGVJGJRQRKVCLG-WCWDXBQESA-N 0.000 description 1
HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
PGGUOGKHUUUWAF-ROUUACIJSA-N Calpeptin Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 PGGUOGKHUUUWAF-ROUUACIJSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
108090000624 Cathepsin L Proteins 0.000 description 1
102000004172 Cathepsin L Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000008934 Muscle Proteins Human genes 0.000 description 1
108010074084 Muscle Proteins Proteins 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
ZFKROSKGZOBXFC-FMQUCBEESA-N N-(1-acetamido-2-oxoheptan-3-yl)-2-[(E)-2-[4-[(4-benzylpiperazin-1-yl)methyl]phenyl]ethenyl]benzamide Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1\C=C\C(C=C1)=CC=C1CN1CCN(CC=2C=CC=CC=2)CC1 ZFKROSKGZOBXFC-FMQUCBEESA-N 0.000 description 1
XHQNDNNAXCATCQ-BMRADRMJSA-N N-(1-acetamido-2-oxoheptan-3-yl)-2-[(E)-2-naphthalen-2-ylethenyl]benzamide Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1\C=C\C1=CC=C(C=CC=C2)C2=C1 XHQNDNNAXCATCQ-BMRADRMJSA-N 0.000 description 1
WSSNPMCMFOVFPN-FOCLMDBBSA-N N-(1-acetamido-2-oxoheptan-3-yl)-2-[(E)-2-phenylethenyl]benzamide Chemical compound CC(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1\C=C\C1=CC=CC=C1 WSSNPMCMFOVFPN-FOCLMDBBSA-N 0.000 description 1
OXAKURHUKQFEMM-FBMGVBCBSA-N N-(1-benzamido-2-oxoheptan-3-yl)-2-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC(=O)C(CCCC)NC(=O)C1=CC=CC=C1\C=C\C1=CC=C(OC)C(OC)=C1 OXAKURHUKQFEMM-FBMGVBCBSA-N 0.000 description 1
YRTJSDZCAANCBV-BMRADRMJSA-N N-(1-benzamido-2-oxohexan-3-yl)-2-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC(=O)C(CCC)NC(=O)C1=CC=CC=C1\C=C\C1=CC=C(OC)C(OC)=C1 YRTJSDZCAANCBV-BMRADRMJSA-N 0.000 description 1
KJSGNKOTIRAOTH-VHEBQXMUSA-N N-(1-benzamido-2-oxohexan-3-yl)-2-[(E)-2-phenylethenyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC(=O)C(CCC)NC(=O)C1=CC=CC=C1\C=C\C1=CC=CC=C1 KJSGNKOTIRAOTH-VHEBQXMUSA-N 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
RIYLNECMTVNMSO-GOTSBHOMSA-N N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 RIYLNECMTVNMSO-GOTSBHOMSA-N 0.000 description 1
208000001738 Nervous System Trauma Diseases 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
150000008062 acetophenones Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical class 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000037007 arousal Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
239000003710 calcium ionophore Substances 0.000 description 1
108010007877 calpain inhibitor III Proteins 0.000 description 1
108010082989 calpeptin Proteins 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
238000002737 cell proliferation kit Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
201000011634 coronary artery vasospasm Diseases 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
150000001944 cysteine derivatives Chemical class 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
VTHMTAYIFZEJIU-BQYQJAHWSA-N ethyl 2-[(e)-2-pyridin-4-ylethenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC=C1\C=C\C1=CC=NC=C1 VTHMTAYIFZEJIU-BQYQJAHWSA-N 0.000 description 1
BIHHBTVQFPVSTE-UHFFFAOYSA-N ethyl 2-bromobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1Br BIHHBTVQFPVSTE-UHFFFAOYSA-N 0.000 description 1
YGNKCTUILKYVIQ-UHFFFAOYSA-N ethyl 3-(naphthalen-2-ylsulfonylamino)benzoate Chemical compound CCOC(=O)C1=CC=CC(NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=C1 YGNKCTUILKYVIQ-UHFFFAOYSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
108010011767 m-calpain Proteins 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001095 motoneuron effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
208000028412 nervous system injury Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
150000002926 oxygen Chemical class 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
238000005897 peptide coupling reaction Methods 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000004623 platelet-rich plasma Anatomy 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
150000003463 sulfur Chemical class 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003021 water soluble solvent Substances 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)

SK1412-2000A 1998-04-20 1999-04-19 Substituované benzamidy, ich príprava a použitie SK14122000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19817461A DE19817461A1 (de)	1998-04-20	1998-04-20	Neue substituierte Benzamide, deren Herstellung und Anwendung
PCT/EP1999/002617 WO1999054293A1 (de)	1998-04-20	1999-04-19	Substituierte benzamide, deren herstellung und anwendung als inhibitoren von cystein-proteasen

Publications (1)

Publication Number	Publication Date
SK14122000A3 true SK14122000A3 (sk)	2001-05-10

Family

ID=7865113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1412-2000A SK14122000A3 (sk)	1998-04-20	1999-04-19	Substituované benzamidy, ich príprava a použitie

Country Status (21)

Country	Link
US (1)	US6436925B1 (cs)
EP (1)	EP1073632A1 (cs)
JP (1)	JP2002512220A (cs)
KR (1)	KR20010042837A (cs)
CN (1)	CN1306509A (cs)
AU (1)	AU743245B2 (cs)
BG (1)	BG104856A (cs)
BR (1)	BR9909776A (cs)
CA (1)	CA2328430A1 (cs)
CZ (1)	CZ20003890A3 (cs)
DE (1)	DE19817461A1 (cs)
HR (1)	HRP20000777A2 (cs)
HU (1)	HUP0101616A3 (cs)
ID (1)	ID26305A (cs)
IL (1)	IL138676A0 (cs)
NO (1)	NO20005265D0 (cs)
PL (1)	PL343466A1 (cs)
SK (1)	SK14122000A3 (cs)
TR (1)	TR200003069T2 (cs)
WO (1)	WO1999054293A1 (cs)
ZA (1)	ZA200006758B (cs)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1193246A4 (en) *	1999-07-01	2003-05-14	Taisho Pharmaceutical Co Ltd	Aminobenzoic DERIVATIVES
AU2001252958A1 (en)	2000-03-23	2001-10-03	Elan Pharmaceuticals, Inc.	Compounds and methods to treat alzheimer's disease
DE60116313T2 (de)	2000-06-30	2006-08-31	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen zur behandlung der alzheimerischen krankheit
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
PE20020506A1 (es) *	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
DE10114762A1 (de) *	2001-03-26	2002-10-02	Knoll Gmbh	Verwendung von Cysteinprotease-Inhibitoren
WO2003002122A1 (en)	2001-06-27	2003-01-09	Elan Pharmaceuticals, Inc.	Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
WO2003013518A1 (en) *	2001-08-03	2003-02-20	Smithkline Beecham Corporation	Alpha-ketoamide derivatives as cathepsin k inhibitors
GB0124933D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
JP2005515254A (ja)	2002-01-17	2005-05-26	スミスクラインビーチャムコーポレーション	カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
JP4472349B2 (ja) *	2002-02-12	2010-06-02	スミスクラインビーチャムコーポレーション	ｐ３８阻害薬として有用なニコチンアミド誘導体
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
ATE443043T1 (de)	2002-11-12	2009-10-15	Merck & Co Inc	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GB0228410D0 (en)	2002-12-05	2003-01-08	Glaxo Group Ltd	Novel Compounds
GB0308201D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308186D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0318814D0 (en) *	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
KR20110098980A (ko) *	2003-12-22	2011-09-02	아지노모토 가부시키가이샤	신규한 페닐알라닌 유도체
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
US20080051416A1 (en) *	2004-10-05	2008-02-28	Smithkline Beecham Corporation	Novel Compounds
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
PT2439205E (pt)	2006-12-29	2015-07-16	Abbvie Deutschland	Compostos de carboxamida e seus usos como inibidores de calpaína
TWI453019B (zh)	2007-12-28	2014-09-21	Abbvie Deutschland	甲醯胺化合物
UY32404A (es) *	2009-01-30	2010-08-31	Novartis Ag	4-aril-butan-1,3-diamidas
TWI519530B (zh)	2009-02-20	2016-02-01	艾伯維德國有限及兩合公司	羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
MX2014011998A (es)	2012-04-03	2015-05-11	Abbvie Deutschland	Compuestos carboxamida y su uso como inhibidores de calpaína v.
CN111978319B (zh)	2014-06-27	2023-08-11	诺格拉制药有限公司	芳基受体调制剂及其制备和使用方法
EP3426674A4 (en)	2016-03-09	2019-08-14	Blade Therapeutics, Inc.	CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2018009417A1 (en)	2016-07-05	2018-01-11	Blade Therapeutics, Inc.	Calpain modulators and therapeutic uses thereof
KR20190063473A (ko)	2016-09-28	2019-06-07	블레이드 테라퓨틱스, 인크.	칼페인 조정자 및 그 치료학적 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH11503417A (ja) *	1995-03-24	1999-03-26	アリス・ファーマシューティカル・コーポレイション	可逆的プロテアーゼインヒビター
EP0923535A4 (en)	1996-08-28	2001-01-10	Smithkline Beecham Corp	CYSTEINE PROTEASE INHIBITORS
EP0944582B1 (de) *	1996-12-11	2003-07-02	Abbott GmbH & Co. KG	Ketobenzamide als calpain-inhibitoren

1998
- 1998-04-20 DE DE19817461A patent/DE19817461A1/de not_active Withdrawn
1999
- 1999-04-19 PL PL99343466A patent/PL343466A1/xx not_active Application Discontinuation
- 1999-04-19 HR HR20000777A patent/HRP20000777A2/hr not_active Application Discontinuation
- 1999-04-19 WO PCT/EP1999/002617 patent/WO1999054293A1/de not_active Ceased
- 1999-04-19 CN CN99807638A patent/CN1306509A/zh active Pending
- 1999-04-19 SK SK1412-2000A patent/SK14122000A3/sk unknown
- 1999-04-19 ID IDW20002113A patent/ID26305A/id unknown
- 1999-04-19 CA CA002328430A patent/CA2328430A1/en not_active Abandoned
- 1999-04-19 CZ CZ20003890A patent/CZ20003890A3/cs unknown
- 1999-04-19 AU AU38186/99A patent/AU743245B2/en not_active Ceased
- 1999-04-19 EP EP99920704A patent/EP1073632A1/de not_active Withdrawn
- 1999-04-19 HU HU0101616A patent/HUP0101616A3/hu unknown
- 1999-04-19 TR TR2000/03069T patent/TR200003069T2/xx unknown
- 1999-04-19 US US09/647,673 patent/US6436925B1/en not_active Expired - Fee Related
- 1999-04-19 JP JP2000544634A patent/JP2002512220A/ja active Pending
- 1999-04-19 KR KR1020007011601A patent/KR20010042837A/ko not_active Withdrawn
- 1999-04-19 IL IL13867699A patent/IL138676A0/xx unknown
- 1999-04-19 BR BR9909776-1A patent/BR9909776A/pt not_active IP Right Cessation
2000
- 2000-10-13 BG BG104856A patent/BG104856A/xx unknown
- 2000-10-19 NO NO20005265A patent/NO20005265D0/no not_active Application Discontinuation
- 2000-11-20 ZA ZA200006758A patent/ZA200006758B/en unknown

Also Published As

Publication number	Publication date
AU3818699A (en)	1999-11-08
CN1306509A (zh)	2001-08-01
NO20005265L (no)	2000-10-19
IL138676A0 (en)	2001-10-31
ID26305A (id)	2000-12-14
HUP0101616A1 (hu)	2001-09-28
PL343466A1 (en)	2001-08-13
CA2328430A1 (en)	1999-10-28
BG104856A (en)	2001-05-31
BR9909776A (pt)	2000-12-19
ZA200006758B (en)	2001-12-12
TR200003069T2 (tr)	2009-01-21
NO20005265D0 (no)	2000-10-19
WO1999054293A1 (de)	1999-10-28
AU743245B2 (en)	2002-01-24
JP2002512220A (ja)	2002-04-23
HUP0101616A3 (en)	2002-10-28
HRP20000777A2 (en)	2001-06-30
KR20010042837A (ko)	2001-05-25
DE19817461A1 (de)	1999-10-21
EP1073632A1 (de)	2001-02-07
US6436925B1 (en)	2002-08-20
CZ20003890A3 (cs)	2001-11-14

Publication	Publication Date	Title
SK14122000A3 (sk)	2001-05-10	Substituované benzamidy, ich príprava a použitie
US7956093B2 (en)	2011-06-07	Substituted amides, their preparation and use
AU721620B2 (en)	2000-07-13	Novel ketobenzamides and their use
US6562827B1 (en)	2003-05-13	Heterocyclically substituted amides used as calpain inhibitors
US6448254B1 (en)	2002-09-10	Substituted amides, their production and their use
JP4621350B2 (ja)	2011-01-26	複素環置換アミド、その製造および使用
JP2011063604A (ja)	2011-03-31	新規の複素環式の置換されたアミド、その製造および使用
SK56599A3 (en)	1999-11-08	Benzamidoaldehydes and their use
SK56699A3 (en)	1999-10-08	Novel heterocyclically substituted benzamides and their use
SK15062000A3 (sk)	2001-05-10	Amidy s heterocyklickými substituentmi, ich príprava a použitie
MXPA00010149A (en)	2001-07-31	Substituted benzamides, their production and their use as cysteine protease inhibitors
MXPA00009969A (en)	2002-03-26	New substituted amides, their production and their use
HK1037371A (en)	2002-02-08	Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
CZ208499A3 (cs)	2000-09-13	Ketobenzamidy a jejich použití
CZ20003867A3 (cs)	2001-01-17	Amidy a jejich použití